Baldwin Wealth Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Baldwin Wealth Partners’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-14,500	Closed	-$148K	–	778
2023 Q3	$148K	Hold	14,500	–	–	0.01%	254
2023 Q2	$109K	Hold	14,500	–	–	0.01%	310
2023 Q1	$128K	Hold	14,500	–	–	0.01%	290
2022 Q4	$132K	Hold	14,500	–	–	0.01%	281
2022 Q3	$117K	Hold	14,500	–	–	0.02%	223
2022 Q2	$109K	Hold	14,500	–	–	0.01%	245
2022 Q1	$136K	Hold	14,500	–	–	0.01%	245
2021 Q4	$116K	Hold	14,500	–	–	0.01%	245
2021 Q3	$141K	Hold	14,500	–	–	0.02%	230
2021 Q2	$144K	Buy	+14,500	New	+$153K	0.02%	231
2017 Q3	–	Sell	-147	Closed	-$5K	–	502
2017 Q2	$5K	Hold	147	–	–	﹤0.01%	446
2017 Q1	$5K	Hold	147	–	–	﹤0.01%	451
2016 Q4	$5K	Hold	147	–	–	﹤0.01%	473
2016 Q3	$7K	Sell	147 -125	-46%	-$6.52K	﹤0.01%	477
2016 Q2	$14K	Hold	272	–	–	﹤0.01%	370
2016 Q1	$15K	Buy	+272	New	+$16K	﹤0.01%	386

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Baldwin Wealth Partners's TEVA Position: Q4 2023 in Review

Baldwin Wealth Partners sold out of Teva Pharmaceuticals (TEVA) in Q4 2023, closing a stake of 14,500 shares — an estimated $148K sold.

Baldwin Wealth Partners first reported a position in TEVA in Q1 2016 and held it in 16 quarters. The position peaked at $148K in Q3 2023. 447 funds tracked by Wall St. Rank hold TEVA as of Q4 2023.

Baldwin Wealth Partners reported no remaining Teva Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Baldwin Wealth Partners sold 14,500 Teva Pharmaceuticals shares in Q4 2023, an estimated $148K.
Baldwin Wealth Partners first reported a position in Teva Pharmaceuticals in Q1 2016 and held it in 16 quarters.
Baldwin Wealth Partners's Teva Pharmaceuticals position peaked at $148K in Q3 2023.
447 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2023.

Based on Baldwin Wealth Partners's 13F filing for Q4 2023, filed 8 Jan 2024.